Vir Biotechnology (VIR) said Thursday that the US Food and Drug Administration granted breakthrough therapy designation to tobevibart and elebsiran for the treatment of chronic hepatitis delta.
The European Medicines Agency also gave priority medicine designation to tobevibart and elebsiran, according to the company.
These designations are backed by safety and efficacy data from the phase 2 Solstice study, Vir added.
Shares of Vir Biotechnology were up nearly 4% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.